Treace Medical Concepts

Treace Medical Concepts, Inc. engages in the design, manufacture, and marketing of orthopedic medical devices and biologic solutions. It offers Lapiplasty, a bunion surgery for three-dimensional bunion correction. It operates and distributes its products and services under the following trademarks: Treace Medical Concepts, Lapiplasty, Fast Grafter, Align My Toe, The Future of Hallux Valgus, Fix It Right The First Time, and Plantar Python. The company was founded by John T. Treace in July 2013 and is headquartered in Ponte Vedra Beach, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Treace Medical Concepts (TMCI) reports stellar revenue growth and innovation plans

Treace Medical Concepts (TMCI) delivered exceptional revenue growth in 2022, exceeding expectations and showcasing strong market positioning. With a focus on innovation, specialized sales strategies, and complementary products, TMCI is poised for continued success. While challenges like sustaining growth exist, the company's strategic investments and upcoming product releases present promising opportunities for future expansion.

Treace Medical Concepts (TMCI) reports robust Q1 growth and raises full-year revenue guidance

Treace Medical Concepts (TMCI) delivered impressive Q1 2023 results, showcasing strong revenue growth and increased market penetration. With raised revenue guidance for the full year and a focus on strategic investments, TMCI is well-positioned for continued success and market expansion.

Treace Medical Concepts reports robust Q2 growth and strategic investments

Treace Medical Concepts (TMCI) delivered strong Q2 results with significant revenue growth, expanded market penetration, and strategic investments in growth initiatives.
While facing a net loss, the company improved adjusted EBITDA and raised full-year revenue guidance, supported by a robust financial position.
Challenges include managing expenses, pricing strategies, and surgeon satisfaction, but opportunities lie in upcoming product launches, reimbursement rates, and surgeon engagement.

Treace Medical Concepts reports strong Q3 revenue growth and outlines future growth strategies

Treace Medical Concepts delivered strong Q3 results with revenue up 23% YoY, despite challenges from soft surgery demand and delayed product launches.
The company's focus on innovation, market expansion, and operational efficiency positions it for future growth and improved financial performance.
While facing short-term challenges, Treace's strategic investments, strong cash position, and product pipeline offer opportunities for sustained growth and market leadership.
Overall, Treace's performance reflects resilience and adaptability in navigating market dynamics, with a clear focus on driving innovation and capturing market opportunities.

Treace Medical Concepts reports robust Q4 earnings and eyes market expansion

Treace Medical Concepts (TMCI) delivered strong financial results in Q4 2023, with revenue growth, positive adjusted EBITDA, and a positive outlook for 2024.
The company's focus on new technologies, market penetration, and efficient sales models positions it well for continued growth and market expansion.
While facing challenges in maintaining gross margins and optimizing sales team productivity, Treace remains optimistic about growth potential and strategic positioning.

Treace Medical Concepts reports robust Q1 growth amidst competitive challenges

Treace Medical Concepts demonstrates strong growth momentum and financial resilience in Q1 2024, driven by product innovation and strategic partnerships.
While facing challenges from increased competition and market pressures, the company remains agile with revised guidance and a focus on cost management.
Opportunities for expansion and differentiation through new product launches and market partnerships position Treace for continued success in the orthopedic medical device sector.

Treace Medical Concepts reports robust Q2 growth and eyes Medicare opportunities

Treace Medical Concepts (TMCI) delivered strong Q2 results and is poised for continued growth with a focus on innovation and market expansion.
While facing challenges in product launch and market competition, the company's commitment to R&D and leveraging regulatory changes provides a solid foundation for future success.
Opportunities in Medicare payment rate increases and new product introductions offer avenues for revenue growth and market leadership in the medical device industry.

Treace Medical Concepts reports Q3 growth, faces patent lawsuit

Treace Medical Concepts showed solid revenue growth in Q3 2024 despite facing a net loss. The company's Nanoplasty system and strategic focus on bunion cases present growth opportunities. Legal challenges and financial losses are key areas of concern.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Akamai Technologies

Coupang

Shift4 Payments

Grocery Outlet

Prospect Capital

Red Rock Resorts

With the earnings-reporting season winding down, the windows for making insider purchases are opening up.

CEOs and Other Insiders Are Buying Shares of These 7 Stocks

NEW YORK--(BUSINESS WIRE)-- #Investigation--The law firm of Kirby McInerney LLP is investigating potential claims against Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NASDAQ: TMCI). The investigation concerns whether Treace and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [Click here to learn more about the investigation] On May 7, 2024, Treace issued a press release reporting its financial results for the first quarter o.

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Treace Medical Concepts, Inc. (TMCI)

Treace Medical Concepts Inc (NASDAQ:TMCI ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Julie Dewey - Chief Communications & Investor Relations Officer John Treace - Founder & CEO Mark Hair - Chief Financial Officer Conference Call Participants Richard Newitter - Truist Securities Drew Ranieri - Morgan Stanley Harrison Parsons - Stephens Simon Nigan - UBS Operator Good day, and thank you for standing by, and welcome to the Treace Medical Concepts First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only-mode.

Treace Medical Concepts Inc (TMCI) Q1 2024 Earnings Call Transcript

Treace Medical Concepts (NASDAQ: TMCI ) stock is falling hard on Wednesday following the release of the medical technology company's Q1 2024 earnings report. The problem comes from the company's guidance for the full year of 2024 in this report.

Why Is Treace Medical Concepts (TMCI) Stock Down 59% Today?

Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.30 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.23 per share a year ago.

Treace Medical Concepts (TMCI) Reports Q1 Loss, Tops Revenue Estimates

Partnership to help pickleball players of all levels with bunions and related midfoot deformities to “get back on their feet” and out on the court Partnership to help pickleball players of all levels with bunions and related midfoot deformities to “get back on their feet” and out on the court

Treace Medical Named First Medical Device Partner and Official Foot and Ankle Solution Partner of the PPA Tour

PONTE VEDRA, Fla., April 17, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today announced that John T.

Treace to Present at Bank of America Health Care Conference

Focus on Foot Health Issue Affecting Millions of People Includes Outreach and Education Efforts to Build Awareness, Reduce Stigma and Correct Misconceptions About This Common Bone Deformity Focus on Foot Health Issue Affecting Millions of People Includes Outreach and Education Efforts to Build Awareness, Reduce Stigma and Correct Misconceptions About This Common Bone Deformity

Treace Announces First Annual National Bunion Day

Alibaba

Enbridge

indie Semiconductor

Old Dominion Freight Line

Insulet

VinFast Auto Ltd

Investors who seek 50% returns in less than 12 months generally will have many choices within stable stocks. The general maxim regarding risk and return applies here: Risky, unstable stocks tend to offer much higher return potential.

7 Stable Stocks for 50% Returns by Early 2025

Company to Host Conference Call on Tuesday, May 7, 2024 at 4:30 pm ET Company to Host Conference Call on Tuesday, May 7, 2024 at 4:30 pm ET

Treace to Report First Quarter 2024 Financial Results

Treace Further Expands Focus on Bunion Deformity Education by Sponsoring First-Ever National Bunion Day in the U.S. on April 16, 2024

Treace Celebrates 100,000 Lapiplasty® 3D Bunion Correction® Patient Milestone

Treace Medical Concepts Inc (TMCI) Q4 2023 Earnings Call Transcript

Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.08 per share a year ago.

Treace Medical Concepts (TMCI) Reports Q4 Loss, Tops Revenue Estimates

PONTE VEDRA, Fla., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided 2024 guidance.

Treace Medical Concepts Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Guidance

Treace Medical Concepts (TMCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Treace Medical Concepts (TMCI) Q4 Earnings Expected to Decline

Company to Host Conference Call on Tuesday, February 27, 2024 at 4:30 pm ET Company to Host Conference Call on Tuesday, February 27, 2024 at 4:30 pm ET

Treace to Report Fourth Quarter and Full-Year 2023 Financial Results

PONTE VEDRA, Fla., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today announced three-year interim clinical data from its ALIGN3D™ post-market study supporting the use of the Lapiplasty® procedure for treating bunions were presented in a podium presentation at the 2024 American College of Foot and Ankle Surgeons (“ACFAS”) Annual Scientific Conference .

Treace Announces Interim 3-Year ALIGN3D™ Clinical Study Data at the 2024 ACFAS Scientific Conference Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure

Company Previews New SpeedPlate™ Configurations, Announces Full Commercial Release of its Micro-Lapiplasty™ System and Limited Clinical Release of its Mini-Adductoplasty™ System and RedPoint™ Patient-Specific Instrumentation Company Previews New SpeedPlate™ Configurations, Announces Full Commercial Release of its Micro-Lapiplasty™ System and Limited Clinical Release of its Mini-Adductoplasty™ System and RedPoint™ Patient-Specific Instrumentation

Treace to Highlight Latest Product Innovations and ALIGN3D™ Study Outcomes at the 2024 ACFAS Annual Scientific Conference

Company to Present at J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 3:45 pm Pacific Time Company to Present at J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 3:45 pm Pacific Time

Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2023 Revenue

PONTE VEDRA, Fla., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T.

Treace to Present at 42nd Annual J.P. Morgan Healthcare Conference

Treace Medical Concepts, Inc. (NASDAQ:TMCI ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Julie Dewey - Chief Communications & Investor Relations Officer John Treace - Chief Executive Officer Mark Hair - Chief Financial Officer Conference Call Participants Danielle Antalffy - UBS Lilia-Celine Lozada - JPMorgan Richard Newitter - Truist Securities Rick Wise - Stifel Andrew Ranieri - Morgan Stanley Ryan Zimmerman - BTIG George Sellers - Stephens Inc. Operator Good day and thank you for standing by. Welcome to Treace Medical Concepts Third Quarter 2023 Earnings Conference Call.

Treace Medical Concepts, Inc. (TMCI) Q3 2023 Earnings Call Transcript

PONTE VEDRA, Fla., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction® Procedure, today reported financial results for the third quarter ended September 30, 2023.

Treace Medical Concepts Reports Third Quarter 2023 Financial Results

PONTE VEDRA, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction® Procedure, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the Stifel 2023 Healthcare Conference on Tuesday, November 14, 2023, beginning at approximately 8:35 am ET.

Treace to Present at Stifel 2023 Healthcare Conference

Treace Medical Concepts, Inc. sells medical device treatments for foot bunions. The global market for bunion correction systems is forecasted to reach $1.25 billion by 2030. Treace Medical's financial trends have shown rising revenue but continued substantial operating losses.

Treace Medical Concepts Continues Growth Investments Despite High Operating Losses

Company to Host Conference Call on Thursday, November 9, 2023 at 4:30 pm ET Company to Host Conference Call on Thursday, November 9, 2023 at 4:30 pm ET

News for Treace Medical Concepts Stock (TMCI)